A new understanding in the epidemiology of melanoma

References

• Hall H, Miller D, Rogers J, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J. Am. Acad. Dermatol.40, 35–42 (1999).
   PubMed Web of Science ®Google Scholar
• Marks R. Epidemiology of melanoma. Clin. Exp. Dermatol.25, 459–463 (2000).
   PubMedGoogle Scholar
• Garbe C, Roderick G, McLeod C, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer89, 1269–1278 (2000).
   PubMed Web of Science ®Google Scholar
• Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in melanoma incidence among whites in the United States. J. Natl Cancer Inst.93, 678–683 (2001).
   PubMed Web of Science ®Google Scholar
• Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983–1996. Int. J. Cancer92, 457–462 (2001).
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol.146, 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Bevona C, Sober AJ. Melanoma incidence trends. Dermatol. Clin.20, 589–595 (2002).
   PubMedGoogle Scholar
• Veierod MB, Weiderpass E, Thorn M et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J. Natl Cancer Inst.95, 1530–1538 (2003).
   PubMed Web of Science ®Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet365, 687–701 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality. Br. J. Dermatol.154, 539–541 (2006).
   PubMedGoogle Scholar
• Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000–2006) and future directions. J. Am. Acad. Dermatol.57(4), 555–572 (2007).
   PubMedGoogle Scholar
• Houghton AN, Polsky D. Focus on melanoma. Cancer Cell2(4), 275–278 (2002).
   PubMed Web of Science ®Google Scholar
• Armstrong B, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res.3, 395–401 (1993).
   PubMed Web of Science ®Google Scholar
• Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer73, 198–203 (1997).
   PubMed Web of Science ®Google Scholar
• Solomon CC, White E, Kristal AR, Vaughan T. Melanoma and lifetime UV radiation. Cancer Causes Control15, 893–902 (2004).
   PubMedGoogle Scholar
• Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma II. Sun exposure. Eur. J. Cancer41, 45–60 (2005).
   PubMed Web of Science ®Google Scholar
• CDC. Sunburn prevalence among adults – United States, 1999, 2003, and 2004. MMWR Morb. Mortal. Wkly Rep.56(21), 524–528 (2007).
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol.150, 179–185 (2004).
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988–2006. J. Invest. Dermatol.130(3), 793–797 (2010).
   PubMed Web of Science ®Google Scholar
• Bradford PT, Anderson WF, Purdue MP et al. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol. Biomarkers Prev.19(9), 2401–2406 (2010).
   PubMedGoogle Scholar
• Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br. J. Dermatol.157, 338–343 (2007).
   PubMed Web of Science ®Google Scholar
• Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch. Dermatol.135, 1451–1456 (1999).
   PubMedGoogle Scholar
• Whiteman DC, Stickley M, Watt P et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J. Clin. Oncol.24(19), 3172–3177 (2006).
   PubMed Web of Science ®Google Scholar
• Dal H, Boldemann C, Lindelöf B. Does relative melanoma distribution by body site 1960–2004 reflect changes in intermittent exposure and intentional tanning in the Swedish population? Eur. J. Dermatol.17(5), 428–434 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas NE, Edmiston SN, Alexander A et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol. Biomarkers Prev.16(5), 991–997 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas NE, Berwick M, Cordiero-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J. Invest. Dermatol.126(8), 1693–1696 (2006).
   PubMed Web of Science ®Google Scholar
• Poynter JN, Elder JT, Fullen DR et al.BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res.16(4), 267–273 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res.16(2), 97–103 (2006).
   PubMedGoogle Scholar
• Hoerster KD, Garrow RL, Mayer JA et al. Density of indoor tanning facilities in 116 large U.S. cities. Am. J. Prev. Med.36, 243–246 (2009).
   PubMedGoogle Scholar
• Lazovich D, Vogel RI, Berwick M et al. Indoor tanning and risk of melanoma: a case–control study in a highly exposed population. Cancer Epidemiol. Biomarkers Prev.19(6), 1557–1568 
(2010).
   PubMed Web of Science ®Google Scholar
• Veierød MB, Parr CL, Lund E, Hjartåker A. Reproducibility of self-reported melanoma risk factors in a large cohort study of Norwegian women. Melanoma Res.18(1), 1–9 (2008).
   PubMedGoogle Scholar
• El Ghissassi F, Baan R, Straif K et al. Special report: policy. A review of human carcinogens – part D: radiation. Lancet Oncol.10, 751–752 (2009).
   PubMed Web of Science ®Google Scholar
• Baade PD, English DR, Youl PH et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch. Dermatol.142, 1422–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Hersey P, Silalr RW, Howe CG et al. Factors related to the presentation of patients with thick primary melanomas. Med. J. Aust.154(9), 583–587 (1991).
   PubMedGoogle Scholar
• Green A. A theory of the site distribution of melanomas: Queensland, Australia. Cancer Causes Control3(6), 513–516 (1992).
   PubMedGoogle Scholar
• Caini S, Gandini S, Sera F et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinic–pathological variant. Eur. J. Cancer45, 3054–3063 (2009).
   PubMedGoogle Scholar
• Franceschi S, Levi F, Randimbison L, La Vecchia C. Site distribution of different types of skin cancer: new aetiological clues. Int. J. Cancer67(1), 24–28 (1996).
   PubMed Web of Science ®Google Scholar
• Bulliard JL, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969–1993. Cancer Causes Control10(5), 407–416 (1999).
   PubMedGoogle Scholar
• Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int. J. Cancer85(5), 627–632 (2000).
   PubMed Web of Science ®Google Scholar
• Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer – the role of sunlight. Adv. Exp. Med. Biol.624, 89–103 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Gomez B, Pollán M, Gustavsson P et al. Cutaneous melanoma: hints from occupational risks by anatomic site in Swedish men. Occup. Environ. Med.61(2), 117–126 (2004).
   PubMedGoogle Scholar
• Olsen CM, Zens MS, Stukel TA et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int. J. Cancer124(4), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Chang YM, Barrett JH, Bishop DT et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int. J. Epidemiol.38, 814–830 (2009).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J. Clin. Oncol.24(19), 3172–3177 (2006).
   PubMed Web of Science ®Google Scholar
• Bulliard JL, Cox B, Elwood JM. Comparison of the site distribution of melanoma in New Zealand and Canada. Int. J. Cancer72, 231–235 (1997).
   PubMedGoogle Scholar
• Perez-Gomez B, Aragones N, Pollan M. Divergent cancer pathways for early onset and late onset cutaneous malignant melanoma. A role for sex–site interaction. Cancer115, 2499 (2010).
   Google Scholar
• Buettner PG, MacLennan R. Geographical variation of incidence of cutaneous melanoma in Queensland. Aust. J. Rural Health16, 269–277 (2008).
   PubMedGoogle Scholar
• Clark LN, Shin DB, Troxel AB, Khan S. Association between the anatomic distribution of melanoma and sex. J. Am. Acad. Dermatol.56, 768–773 (2007).
   PubMedGoogle Scholar
• Pruthi DK, Guilfoyle R, Nugent Z, Wiseman MC, Demers AA. Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. J. Am. Acad. Dermatol.61(1), 44–50 (2009).
   PubMedGoogle Scholar
• Schmidt A, Nanney LB, Boyd AS, King LE, Ellis DL. Oestrogen receptor-β expression in melanocytic lesions. Exp. Dermatol.15, 971–980 (2006).
   PubMedGoogle Scholar
• Driscoll MS, Grant-Kels JM. Nevi and melanoma in pregnancy. Dermatol. Clin.24, 199–204 (2006).
   PubMedGoogle Scholar
• de Giorgi V, Mavilla C, Massi D et al. Estrogen receptor expression in cutaneous melanoma. Arch. Dermatol.145, 30–36 (2009).
   PubMedGoogle Scholar
• Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: III. Reproductive factors and oral contraceptive use. Am. J. Epidemiol.141, 943–950 (1995).
   PubMedGoogle Scholar
• Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int. J. Epidemiol.27, 751–757 (1998).
   PubMed Web of Science ®Google Scholar
• Koomen ER, Joosse A, Herings et al. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study. Ann. Oncol.20(2), 358–364 (2009).
   PubMedGoogle Scholar
• Adegbidi H, Yedomon H, Atadokpede F, Balley-Pognon MC, do Ango-Padonou F. Skin cancers at the National University Hospital of Cotonou from 1985 to 2004. Int. J. Dermatol.46(Suppl. 1), 26–29 (2007).
   PubMedGoogle Scholar
• Asuquo ME, Ebughe G. Cutaneous cancers in Calabar, Southern Nigeria. Dermatol. Online J.15(4), 11 (2009).
   PubMedGoogle Scholar
• Seleye-Fubara D, Etebu EN. Histological review of melanocarcinoma in Port Harcourt. Niger. J. Clin. Pract.8(2), 110–113 (2005).
   PubMedGoogle Scholar
• Swan MC, Hudson DA. Malignant melanoma in South Africans of mixed ancestry: a retrospective analysis. Melanoma Res.13(4), 415–419 (2003).
   PubMedGoogle Scholar
• Uehara S, Kamo R, Harada T, Ishii M. Survival analysis of malignant melanoma in Japan – multivariate analysis of prognostic factors. Osaka City Med. J.55(1), 35–52 (2009).
   PubMedGoogle Scholar
• Cicarma E, Juzeniene A, Porojnicu A, Bruland O, Moan J. Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966–2007. J. Photochem. Photobiol. B Biol.101(2), 174–178 (2010).
   PubMedGoogle Scholar
• Doherty VR, Brewster DH, Jensen S, Gorman D. Trends in skin cancer incidence by socioeconomic position in Scotland, 1978–2004. Br. J. Cancer102, 1661–1664 (2010).
   PubMedGoogle Scholar
• Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br. J. Dermatol.157, 338–343 (2007).
   PubMed Web of Science ®Google Scholar
• Amerio P, Manzoli L, Auriemma M, Carbone A, Proietto G, Angelucci D. Epidemiology and clinical and pathologic characteristics of cutaneous malignant melanoma in Abruzzo (Italy). Int. J. Dermatol.48, 718–722 (2009).
   PubMedGoogle Scholar
• Naldi L, Altieri A, Imberti GL, Gallus S, Bosetti C, La Vecchia C. Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomical locations (Italy). Cancer Causes Control16, 893–899 (2005).
   PubMed Web of Science ®Google Scholar
• Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig–Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br. J. Dermatol.149(6), 1200–1206 (2003).
   PubMed Web of Science ®Google Scholar
• Zemelman V, Roa J, Ruiz T, Valenzuela CY. Malignant melanoma in Chile: an unusual distribution of primary sites in men from low socioeconomic strata. Clin. Exp. Dermatol.31, 335–338 (2006).
   PubMedGoogle Scholar
• Ferrari Júnior NM, Muller H, Ribeiro M, Maia M, Sanches Júnior JA. Cutaneous melanoma: descriptive epidemiological study. Sao Paulo Med. J.126(1), 41–47 (2008).
   PubMedGoogle Scholar
• Noorbala MT, Kafaie P. Analysis of 15 years of skin cancer in central Iran (Yazd). Dermatol. Online J.13(4), 1 (2007).
   PubMedGoogle Scholar
• Nasseri K, Mills PK, Allan M. Cancer incidence in the Middle Eastern population of California, 1988–2004. Asian Pac. J. Cancer Prev.8(3), 405–411 (2007).
   PubMed Web of Science ®Google Scholar
• Woodall CE, Martin RCG, Stromberg AJ et al. Do melanoma patients from southern climates have a worse outcome than those from northern climates? Am. Surg.75, 687–692 (2009).
   PubMedGoogle Scholar
• Cockburn M, Hamilton A, Mack T. The simultaneous assessment of constitutional behavioral, and environmental factors in the development of large nevi. Cancer Epidemiol. Biomarkers Prev.16(2), 200–206 (2007).
   PubMedGoogle Scholar
• Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations – US Surveillance, Epidemiology and End Results (SEER) Program, 1992–2001. Arch. Dermatol.141(4), 477–481 
(2005).
   PubMed Web of Science ®Google Scholar
• Rouhani P. Hu S, Kirsner RS. Melanoma in Hispanic and black Americans. Cancer Control15, 248–253 (2008).
   PubMedGoogle Scholar
• Cormier JN, Xing Y, Ding M et al. Ethnic differences among patients with cutaneous melanoma. Arch. Intern. Med.166, 1907–1914 (2006).
   PubMedGoogle Scholar
• Agredano YZ, Chan JL, Kimball RC, Kimball AB. Accessibility to air travel correlates strongly with increasing melanoma incidence. Melanoma Res.16(1), 77–81 (2006).
   PubMed Web of Science ®Google Scholar
• Haldorsen T, Reitan J, Tveten U. Cancer incidence among Norwegian airline cabin attendants. Int. J. Epidemiol.30, 825–830 (2001).
   PubMed Web of Science ®Google Scholar
• Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev. Anticancer Ther.9(5), 587–595 (2009).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Haigh P, DiFronzo L, McCready D. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can. J. Surg.46, 419–426 (2003).
   PubMedGoogle Scholar
• Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 and 3 cm. N. Engl. J. Med.318, 1159–1162 (1988).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Cascinelli N. Narrow excision (1-cm margin) a safe procedure for thin cutaneous melanoma. Arch. Surg.126, 438–441 (1991).
   PubMedGoogle Scholar
• Balch CM, Soong SJ, Smith T et al. Long-term results of a prospective surgical trial comparing 2-cm v. 4-cm excision margins for 470 patients with 1 to 4-mm melanomas. Ann. Surg. Oncol.8, 101–108 (2001).
   PubMed Web of Science ®Google Scholar
• Fukuda H, Hiratsuka J, Kobayashi T et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Aust. Phys. Eng. Sci. Med.26(3), 97–103 (2003).
   PubMedGoogle Scholar
• McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol.44(11), 1039–1046 (2008).
   PubMed Web of Science ®Google Scholar
• Testori A, Rutkowski P, Marsden J et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann. Oncol.20(Suppl. 6), vi22–vi29 (2009).
   PubMed Web of Science ®Google Scholar
• Santa Cruz GA, Bertotti J, Marín J et al. Dynamic infrared imaging of cutaneous melanoma and normal skin in patients treated with BNCT. Appl. Radiat. Isot.67(Suppl. 7–8), S54–S58 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson MA, Burmeister B, Thompson JF et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J. Clin. Oncol.27(Suppl. 18) (2009) (Abstract LBA9084).
   Google Scholar
• Hersey P. Immunotherapy for melanoma. Asia Pac. J. Clin. Oncol.6(Suppl. 1), S2–S8 (2010).
   Google Scholar
• Vuoristo MS, Hahka-Kemppinen M, Parvinen LM et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α in patients with advanced melanoma. Melanoma Res.15, 291–296 (2005).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon α adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J. Natl Cancer Inst.102(7), 493–501 (2010).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am.6(Suppl. 1), S11–S14 (2000).
   PubMed Web of Science ®Google Scholar
• Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene29(41), 5545–5555 (2010).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al. High dose and low-dose interferon α-2b in high risk melanoma: first analysis of Intergroup trial E1690/S9111/C9190. J. Clin. Oncol.18(12), 2444–2458 (2000).
   PubMed Web of Science ®Google Scholar
• Davis ID, Skak K, Smyth MJ et al. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin. Cancer Res.13, 6926–6932 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson JA, Curti BD, Redman BG et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol.26, 2034–2039 (2008).
   PubMed Web of Science ®Google Scholar
• Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother.33(5), 547–556 (2010).
   PubMedGoogle Scholar
• Ellyard JI, Quah BJ, Simson L, Parish CR. Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1. J. Immunother.33(5), 443–452 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10, 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Gore M. Randomised adjuvant trials in melanoma: surgical and systemic. Semin. Oncol.34, 509–515 (2007).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol.26(20), 3445–3454 (2008).
   PubMed Web of Science ®Google Scholar
• Topalian SL, Chen K, Taube J et al. Immunology. In: Cutaneous Melanoma (5th Edition). Balch C, Houghton AN, Sober AJ et al. (Eds). Quality Medical Publishing, MO, USA, 865–882 (2009).
   Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer7, 95–106 (2007).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther.3, 15–25 (2010).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wllner I et al. Phase I study of a single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Atkins MB. The treatment of metastatic melanoma chemotherapy and biologics. Curr. Opin. Oncol.9(2), 205–213 (1997).
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. Cancer115, 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist10, 16 (2010).
   Google Scholar
• Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.21(17), 2823–2830 (2009).
   Google Scholar
• Fisher DE, Barnhill R, Hodi FS et al. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res.23, 14–26 (2010).
   PubMedGoogle Scholar
• Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr. Opin. Oncol.22, 178–182 (2010).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353, 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar